ARTEMIS MRI-TRUS Fusion Biopsy: Advancing Prostate Cancer Diagnostics Across Europe
Meeting the Evolving Needs of European Urology Prostate cancer remains a leading health concern across Europe, necessitating diagnostic tools that are both precise and adaptable to diverse clinical settings. The ARTEMIS MRI-TRUS Fusion Biopsy system addresses these needs by integrating multiparametric MRI with real-time ultrasound, offering enhanced accuracy in detecting clinically significant prostate cancers. PMC Key Advantages of ARTEMIS for European Healthcare Providers Enhanced Detection Accuracy Targeted Biopsies: ARTEMIS enables precise targeting of MRI-identified lesions, improving the detection rate of significant prostate cancers. Reduced Overdiagnosis: By focusing on clinically relevant areas, the system minimizes the identification of indolent tumors, aligning with best practices in patient care. Seamless Integration into Clinical Workflows Flexible Biopsy Approaches: Supports both transrectal and transperineal procedures, allowing clinicians to choose the mos...